文献速递类风湿关节炎

类风湿关节炎治疗越早越好:但能否检测到机会窗?

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
PubMed 文献 · RMD Open · 2020-01-01

该研究基于BeSt(n=508)和IMPROVED(n=479)两项随机试验中症状持续时间<2年的RA患者,采用Cox回归分析症状持续时间与持续无药缓解(sDFR)的关系。结果显示sDFR概率随时间逐渐下降,慢作用单药治疗者下降更快,线性模型拟合不劣于非线性模型,未发现2年症状持续时间内的机会窗证据。

要点

  • 症状持续时间与sDFR概率呈线性下降关系,未发现 hyperbolic 或平台期。
  • 慢作用单药治疗者sDFR概率下降比快作用联合治疗更陡峭。
  • 在2年症状持续时间内未观察到机会窗(WOO)存在的证据。

核心结论

  • 症状持续时间与sDFR概率呈线性下降关系,未发现机会窗证据。
  • 慢作用单药治疗者sDFR概率下降最快,但所有模型均未趋近于零。

研究设计与样本

  • 基于BeSt(n=508)和IMPROVED(n=479)两项随机试验,纳入症状持续时间<2年的RA患者。
  • 采用Cox回归分析症状持续时间与sDFR的关联形状,并用似然比检验比较线性与非线性模型拟合。

主要发现

  • BeSt快作用治疗54/226例、IMPROVED 110/421例、BeSt慢作用治疗53/243例达到sDFR。
  • 非线性模型未优于线性模型(快作用BeSt p=0.743,IMPROVED p=0.337;慢作用BeSt p=0.609)。
  • 慢作用单药治疗后线性模型下降更陡峭,但所有模型均未随症状持续时间延长而趋近零概率。

关键数值与推荐

  • sDFR定义为Disease Activity Score<1.6且至少1年未使用改善病情抗风湿药。

临床怎么用

  • 临床应尽早启动治疗,但不应依赖2年内存在机会窗的假设来延迟治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic ('curved') decline in the chance to achieve the outcome sustained drug-free remission (sDFR) over time, after which achieving sDFR is not possible anymore, or by a more gradual linear decline approaching zero chance to achieve sDFR. METHODS: Patients with RA (symptom duration <2 years) were included from two randomised trials: BehandelStrategieën (BeSt), n=508 and Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED), n=479. Cox-regression was performed to assess the shape of the association between symptom duration and sDFR (Disease Activity Score<1.6, no disease-modifying anti-rheumatic drugs for ≥1 year) for patients starting slow-acting monotherapy (IMPROVED, BeSt) or fast-acting combination therapy (BeSt). Likelihood ratio tests were used to compare the fit of linear and non-linear models in both databases separately. Predictions from the best fitting models were used to assess whether the absolute risk to achieve sDFR approaches zero with increasing symptom duration. RESULTS: In BeSt and IMPROVED, 54/226 and 110/421 patients achieved sDFR with fast-acting treatment, and 53/243 (BeSt) with slow-acting treatment. Non-linear models did not fit better than linear models (fast-acting treatment BeSt p=0.743, IMPROVED p=0.337; slow-acting treatment BeSt p=0.609). After slow-acting monotherapy, linear models declined steeper. None of the models approached zero chance to achieve sDFR over time. CONCLUSIONS: The chance to achieve sDFR decreased gradually over time, and decreased fastest in patients starting slow-acting monotherapy. In both treatment groups, we found no evidence for a WOO within 2 years symptom duration.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Bergstra SA, Van Der Pol JA, Riyazi N, et al. Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity? RMD Open. 2020. PMID: 32471854. doi:10.1136/rmdopen-2020-001242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。